



4955 Avalon Ridge Parkway · Norcross, GA 30071
Telephone (770) 242-8723 Fax (770) 242-8639

Contact

Media: Bill Wells – 770-242-8723

SpectRx, Inc. Completes Name Change to Guided Therapeutics, Inc. Receives New Stock Ticker Symbol - GTHP

NORCROSS, GA (May 8, 2008) – [Guided Therapeutics, Inc.](#) (GT) (Pink Sheets: GTHP) today announced that it was issued stock ticker symbol GTHP. GT, formally known as SpectRx, Inc., was previously traded under the stock symbol SPRX.

“The company name and stock ticker change reflect the company’s focus on developing our non-invasive cancer detection technology,” said Mark L. Faupel, Ph.D., GT President and CEO. “We plan to complete the corporate changeover in the coming days with an updated web site.”

The company’s new CUSIP number is 40171F 105. The new ISIN number for the company is US40171F1057.

About Guided Therapeutics

Guided Therapeutics, Inc. (Pink Sheets: GTHP) is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. The company also owns technology for measuring substances in interstitial fluid, a secondary circulatory system in the body that surrounds the cells. For more information, visit GT’s web site www.guidedtherapeutics.com.

The Guided Therapeutics LightTouch™ Non-invasive Cervical Cancer Detection Device is an investigational device and is limited by federal law to investigational use.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’s actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’s reports filed with the SEC, including Guided Therapeutics’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 and subsequent quarterly reports.

###END###